Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
